MedTrace Logo

INCB040093 and INCB040093 Combined With Itacitinib (INCB039110) in Relapsed/Refractory Hodgkin Lymphoma

NCT02456675 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2018-01-12

No results posted yet for this study

Summary

A Phase 2, open-label study to evaluate the safety and efficacy of INCB040093 as monotherapy and as combination therapy with itacitinib (INCB039110) in subjects with relapsed or refractory Hodgkin Lymphoma.

Conditions

  • Refractory Hodgkin Lymphoma
  • Recurrent Adult Hodgkin's Lymphoma

Interventions

DRUG

INCB040093 Monotherapy

INCB040093 sustained release (SR) tablets will be administered orally twice daily (BID) without regard to food.

DRUG

INCB040093

INCB040093 sustained release (SR) tablets will be administered orally twice daily (BID) without regard to food.

DRUG

itacitinib

The dose of itacitinib will be given orally once daily (QD).

Sponsors & Collaborators

Principal Investigators

  • Peter Langmuir, MD · Incyte Corporation

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2016-12-16
Completion
2016-12-16

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02456675 on ClinicalTrials.gov